Abstract Preclinical and early clinical studies of the adenovirus-based vectors for gene therapy have shown considerable promise for the future. Use of adenoviral vectors in gene therapy is, however, limited by the lack of adenoviral receptors on targeted cell types, induction of neutralizing antibodies, short blood circulation half-life of adenovirus (Ad), hepatotoxicity and low selective accumulation in the target disease site. Researchers have shown that chemical modification of the Ad surface may be an effective means to overcome the current limitations of Ad-mediated gene transfer. In comparison, a small number of studies have addressed these issues by developing cationic lipid-based nanoparticles as an Ad-complexing formulation. Findings from these studies indicate that Ad complexation with cationic lipid-based nanoparticles is an effective and simple means to overcome the lack of receptors in target cells in vitro and to reduce the immunogenicity and hepatotoxicity of Ad vectors in vivo. In contrast, findings about the effect of cationic nanoparticle complexation in increasing the Ad accumulation in the target site in vivo are not consistent among studies. A definitive conclusion cannot be drawn at the current state due to the limited number of studies but the reasons for the discrepancy may include the differences in the lipid composition and the structure of cationic lipid-based nanoparticles. This review gives a comprehensive overview of current status in the development of cationic lipid-based nanoparticles as a vehicle to overcome the challenges of adenoviral vectors.
cationic            0.9999999999846523^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ion                   

gene                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Gene_therapy          

cells                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cell_(biology)        

disease                       0.9463451423494919^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Infection             

nanoparticles                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Nanoparticle          

chemical modification         0.9999999950905476^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Chemical_synthesis    

cationic                      0.9999999999846523^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ion                   

nanoparticle                  0.9999999999631655^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Nanoparticle          

immunogenicity                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Immunogenicity        

nanoparticles                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Nanoparticle          

receptors                     0.9999999918715048^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Receptor_(biochemistry)

vectors                       0.9999997882016711^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Plasmid               

hepatotoxicity                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatotoxicity        

adenoviral                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Adenoviridae          

nanoparticles                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Nanoparticle          

adenoviral                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Adenoviridae          

antibodies                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antibody              

gene therapy                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Gene_therapy          

cationic                      0.9999999999846523^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ion                   

nanoparticles                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Nanoparticle          

cell types                    0.9999996323759427^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cell_type             

induction                     0.9963354708349929^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Inductive_reasoning   

adenovirus                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Adenoviridae          

receptors                     0.9999999918715048^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Receptor_(biochemistry)

vectors                       0.9999997882016711^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Plasmid               

cationic                      0.9999999999846523^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ion                   

cationic                      0.9999999999846523^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ion                   

half-life                     0.9999966702694976^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Half-life             

vectors                       0.9999997882016711^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Plasmid               

complexation                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Coordination_complex  

complexation                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Coordination_complex  

Preclinical                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Pre-clinical_development

hepatotoxicity                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatotoxicity        

gene therapy                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Gene_therapy          

clinical studies              1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Clinical_trial        

vectors                       0.9999997882016711^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Plasmid               

lipid                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Lipid                 

blood circulation             0.9988766244665951^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Circulatory_system    

adenoviral                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Adenoviridae          

